Shah Keeren Rameshchandra
SEC insider (Form 3/4/5 filer). CIK 0002125071. Chief Financial Officer at OKYO Pharma Ltd (OKYO) and 1 other issuer. 1 reported Form 4/5 transaction since Sep 2024; latest on Jun 8, 2026. Located in LONDON.
Companies Shah Keeren Rameshchandra has filed insider reports for
- OKYO Pharma Ltd (OKYO): Officer, Chief Financial Officer
- Tiziana Life Sciences Ltd (TLSA): Officer, CHIEF OPERATING & FIN. OFFICER
Shah Keeren Rameshchandra
CIK: 0002125071
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
